[Utility of PET-18FDG in primary tumor site in a patient with cerebral metastases].
Suárez Fernández
J P
JP
PET, Centro PET Complutense, Madrid, Spain. director@petmadris.com
Serna Macías
J A
JA
Domínguez Grande
M L
ML
Liaño
H
H
Pozo
M A
MA
Maldonado Suárez
A
A
D000230:Adenocarcinoma / Q000150:complications / Q000000981:diagnostic imaging* / Q000556:secondary*; D000368:Aged; D000544:Alzheimer Disease / Q000150:complications; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D001932:Brain Neoplasms / Q000150:complications / Q000000981:diagnostic imaging* / Q000556:secondary*; D017809:Fatal Outcome; D005260:Female; D019788:Fluorodeoxyglucose F18; D020233:Gait Disorders, Neurologic / Q000209:etiology; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications / Q000000981:diagnostic imaging*; D008207:Lymphatic Metastasis; D001523:Mental Disorders / Q000209:etiology; D008636:Mesencephalon / Q000000981:diagnostic imaging* / Q000473:pathology; D009382:Neoplasms, Unknown Primary / Q000000981:diagnostic imaging*; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D013788:Thalamus / Q000000981:diagnostic imaging* / Q000473:pathology
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18